{{scheme.chgp}}%
{{scheme.chgp}}%
No Matches Found
{{scheme.chgp}}%
No Matches Found
No Matches Found
Is Genprex, Inc. technically bullish or bearish?
As of June 2, 2025, Genprex, Inc. is in a mildly bearish trend, supported by bearish daily moving averages and indicators, despite some mild bullish signals on the MACD and KST.
Who are in the management team of Genprex, Inc.?
As of March 2022, the management team of Genprex, Inc. includes J. Rodney Varner as Chairman, President, CEO, and Secretary, along with independent directors Brent Longnecker, Jose Moreno Toscano, and William Wilson.
What does Genprex, Inc. do?
Genprex, Inc. is a clinical-stage gene therapy company focused on developing cancer therapies, with a market cap of USD 8.70 million and recent net profits of -4 million. The company operates in the Pharmaceuticals & Biotechnology industry and has no dividend yield.
How big is Genprex, Inc.?
As of Jun 18, Genprex, Inc. has a market capitalization of 8.70 million, with net sales of 0.00 million and a net profit of -19.11 million over the last four quarters. The company reported shareholder's funds of 1.62 million and total assets of 4.12 million as of Dec 24.
{{list.post_title}}
{{list.post_excerpt}}
{{list.post_title}}
{{list.post_excerpt}}
